Form
SCHEDULE 13G/A
Passive or exempt beneficial ownership filing.
Advent Life Sciences LLP - 09 Jul 2025 SCHEDULE 13G/A Report for Acutus Medical, Inc. Common Stock, par value $0.001 per share (AFIB)
- Filing manager
- Advent Life Sciences LLP
- Reporting owner
- Advent Life Sciences LLP
- Beneficially owned shares
- 0 shares
- Large-stake signal
-
Ownership
0%Beneficial ownership of this reported class.
Shares
0 sharesShares beneficially owned as disclosed.
Event date
09 Jul 2025Date tied to the ownership event or amendment.
Accepted by SEC
17 Feb 2026EDGAR acceptance date.
How to read this large-stake filing
- Schedule 13D/G filings focus on beneficial ownership stakes, not a full portfolio.
- Compare this filing with the holder history and issuer page before treating the percentage as a current position.
- Use amendments to understand whether the disclosed stake increased, decreased, or changed reporting status.
- Class ownership
- 0%
- Symbol
- AFIB
- SEC form
- SCHEDULE 13G/A
- Accepted by SEC
- 17 Feb 2026, 20:49:12 UTC
- Event date
- 09 Jul 2025
- Source filing
- View source filing
Ownership signal
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Subject security
Names, identifiers, and filing context for this profile.
1 source field
Source evidence
Original filing metadata and source links for verification.
4 source fields
Key filing fact
Advent Life Sciences LLP disclosed 0% ownership in Acutus Medical, Inc. Common Stock, par value $0.001 per share (AFIB) on 09 Jul 2025.
Key facts
- Advent Life Sciences LLP filed SCHEDULE 13G/A for Acutus Medical, Inc. Common Stock, par value $0.001 per share (AFIB).
- Disclosed ownership: 0%.
- Date of event: 09 Jul 2025.
Change
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Feb 2026, 20:49.
Research use
- This page turns one Schedule 13D/G filing into a quick large-stake read before the raw reporting-person rows.
- Use the linked SEC filing as the source of truth for ownership percentages, shares, and reporting-party details.
Evidence
Backed by Schedule 13D/13G
View source filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting persons
Disclosed reporting parties (3)
Names, ownership percentages, voting power, signatures, titles, and CIKs as disclosed in this Schedule 13D/G filing.
| Name | Ownership | Shares owned | Sole voting power | Shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Advent Life Sciences LLP | 0% | 0 | 0 | 0 | /s/ Shahzad Malik | General Partner of Advent Life Sciences LLP | |
| Advent Life Sciences Fund I LP | 0% | 0 | 0 | 0 | /s/ Shahzad Malik | General Partner of Advent Life Sciences LLP acting in its capacity as Manager of Advent Life Sciences Fund I LP | |
| Shahzad Malik | 0.08% | 22,757 | 3,281 | 0 | /s/ Shahzad Malik | Shahzad Malik |
CIK / CUSIP context first